DAFNA Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

DAFNA Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-2,430	Closed	-$403K	–	83
2015 Q3	$403K	Buy	2,430 +430	+22%	+$94.6K	0.4%	62
2015 Q2	$483K	Hold	2,000	–	–	0.41%	52
2015 Q1	$564K	Sell	2,000 -19,900	-91%	-$4.31M	0.43%	46
2014 Q4	$3.42M	Buy	21,900 +19,900	+995%	+$3.68M	2.7%	11
2014 Q3	$473K	Hold	2,000	–	–	0.48%	38
2014 Q2	$473K	Hold	2,000	–	–	0.45%	34
2014 Q1	$660K	Sell	2,000 -7,598	-79%	-$2.56M	0.57%	35
2013 Q4	$655K	Hold	9,598	–	–	0.67%	33
2013 Q3	$663K	Sell	9,598 -402	-4%	-$19.8K	0.72%	36
2013 Q2	$448K	Buy	+10,000	New	+$342K	0.66%	35

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Carmignac Gestion Paris, France $7.71B AUM 4.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DAFNA Capital Management's ICPT Position: Q4 2015 in Review

DAFNA Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2015, closing a stake of 2,430 shares — an estimated $403K sold.

DAFNA Capital Management first reported a position in ICPT in Q2 2013 and held it in 10 quarters. The position peaked at $3.42M in Q4 2014. 172 funds tracked by Wall St. Rank hold ICPT as of Q4 2015.

DAFNA Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2015 after selling out during the quarter.
DAFNA Capital Management sold 2,430 Intercept Pharmaceuticals, Inc. shares in Q4 2015, an estimated $403K.
DAFNA Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 10 quarters.
DAFNA Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $3.42M in Q4 2014.
172 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2015.

Based on DAFNA Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.